NRNP 6665 PMHNP Care Across the Lifespan I Midterm
Exam Prep Document | 2026/2027 Edition | 250 Verified
Questions
NRNP 6665 PMHNP Care Across the Lifespan I Midterm Exam 2026-2027 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive midterm exam preparation resource for NRNP 6665 PMHNP Care Across the
Lifespan I contains 250 verified questions with detailed rationales. Designed for the 2026/2027
academic year, it covers all major content areas including psychiatric assessment, therapeutic
interventions, and lifespan considerations. Each question includes evidence-based explanations to
reinforce learning and ensure exam readiness. This document is pass guaranteed and A+ graded.
Abstract:
This document provides a rigorous preparation tool for the NRNP 6665 PMHNP Care Across the Lifespan I
midterm examination, featuring 250 verified questions with detailed rationales. The content is meticulously aligned
with the 2026/2027 academic year curriculum and the latest psychiatric-mental health nursing standards. Each
question is designed to test critical thinking and clinical application across diverse patient populations, from
children to older adults. The rationales include evidence-based explanations, distractor analyses, and references to
key sources such as the DSM-5-TR and APA guidelines. This resource emphasizes safe, effective, and culturally
competent care, ensuring students are well-prepared for both the exam and future clinical practice. The pass
guarantee and A+ grading reflect the high quality and accuracy of the material.
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of 1-50 Therapeutic communication, ethical 20%
Psychiatric-Mental Health principles, legal issues, cultural competence,
Nursing patient advocacy
Psychiatric Assessment and 51-100 Mental status exam, diagnostic criteria 20%
Diagnosis (DSM-5-TR), risk assessment, differential
diagnosis, biopsychosocial formulation
Psychopharmacology 101-150 Antidepressants, antipsychotics, mood 20%
stabilizers, anxiolytics, stimulants, side
effect management
Therapeutic Interventions 151-200 Cognitive-behavioral therapy, motivational 20%
interviewing, crisis intervention,
psychoeducation, family therapy
Lifespan Considerations 201-250 Child and adolescent psychiatry, geriatric 20%
psychiatry, perinatal mental health,
developmental transitions, special
populations
Page 1
,Q1. A patient with treatment-resistant depression has failed adequate trials of three SSRIs and one
SNRI. They also have a history of hypomania when previously treated with venlafaxine. Which
augmentation strategy is most appropriate while minimizing mood destabilization risk?
A. Add aripiprazole 2 mg daily
B. Add lithium 300 mg twice daily
C. Switch to phenelzine 45 mg daily
D. Add bupropion 150 mg extended-release daily
Correct Answer: A. Add aripiprazole 2 mg daily
Rationale: Aripiprazole is FDA-approved for adjunctive treatment of major depressive disorder and has
a low risk of inducing mania compared to other agents. Lithium is effective but requires monitoring and
may not be first-line augmentation for unipolar depression. Phenelzine is a potent MAOI with dietary
restrictions and higher risk. Bupropion can lower seizure threshold and is not recommended in patients
with bipolar diathesis.
Why Wrong:
B - Lithium requires serum monitoring and is not first-line augmentation for unipolar depression; it
also carries risk of toxicity.
C - Phenelzine has significant dietary restrictions and MAOI interactions; not first-line for
augmentation.
D - Bupropion can lower seizure threshold and may destabilize mood in patients with bipolar
diathesis.
Reference: Stahl, S.M. (2021). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 6; APA Practice
Guideline for MDD (2010, updated 2023).
Q2. Which neurobiological finding best explains the therapeutic lag of SSRIs in major depressive
disorder despite immediate increases in synaptic serotonin?
A. Downregulation of presynaptic 5-HT1A autoreceptors
B. Upregulation of postsynaptic 5-HT2A receptors
C. Inhibition of serotonin transporter (SERT) within hours
D. Desensitization of somatodendritic 5-HT1A autoreceptors
Correct Answer: D. Desensitization of somatodendritic 5-HT1A autoreceptors
Rationale: SSRIs rapidly block SERT, increasing extracellular serotonin, but clinical response requires
weeks because somatodendritic 5-HT1A autoreceptors in the raphe nuclei must desensitize to allow
sustained serotonin release. Downregulation of presynaptic 5-HT1A autoreceptors (A) is less relevant;
upregulation of 5-HT2A (B) is associated with side effects; SERT inhibition (C) occurs immediately but
does not explain the lag.
Why Wrong:
A - Presynaptic 5-HT1A autoreceptors are on terminals, but their downregulation is not the primary
mechanism for the lag.
B - Upregulation of 5-HT2A receptors is linked to anxiety and insomnia, not therapeutic lag.
C - SERT inhibition occurs within hours, but does not account for the delayed clinical effect.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 15; Stahl, S.M. (2021).
Stahl's Essential Psychopharmacology, Ch. 6.
Page 2
,Q3. A patient with schizophrenia is stabilized on haloperidol decanoate 100 mg IM every 4 weeks.
They present with acute dystonia after a missed dose. Which intervention is most appropriate for
immediate management?
A. Administer benztropine 2 mg IM
B. Increase haloperidol dose to 150 mg
C. Start olanzapine 10 mg orally
D. Give diphenhydramine 50 mg IV
Correct Answer: A. Administer benztropine 2 mg IM
Rationale: Acute dystonia is an extrapyramidal symptom (EPS) caused by dopamine blockade.
Anticholinergic agents like benztropine IM provide rapid symptom relief. Diphenhydramine IV (D) is also
effective but more sedating; benztropine is preferred for dystonia. Increasing haloperidol (B) would
worsen EPS. Starting olanzapine (C) does not address the acute dystonia.
Why Wrong:
B - Increasing the dose of a high-potency antipsychotic would exacerbate EPS.
C - Olanzapine has lower EPS risk but does not treat acute dystonia.
D - Diphenhydramine IV is effective but more sedating; benztropine IM is more specific.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 16; APA Practice
Guideline for Schizophrenia (2021).
Q4. A patient with generalized anxiety disorder (GAD) has a history of substance use disorder
(alcohol in remission). Which first-line pharmacotherapy is safest given this history?
A. Buspirone 10 mg three times daily
B. Lorazepam 0.5 mg three times daily as needed
C. Sertraline 50 mg daily
D. Hydroxyzine 25 mg four times daily
Correct Answer: C. Sertraline 50 mg daily
Rationale: SSRIs (sertraline) are first-line for GAD and have no abuse potential, making them safest in
patients with substance use history. Buspirone (A) is non-addictive but less effective for GAD.
Benzodiazepines (B) carry high abuse risk. Hydroxyzine (D) is sedating and not first-line.
Why Wrong:
A - Buspirone is non-addictive but less effective than SSRIs for GAD.
B - Benzodiazepines have high abuse potential in patients with substance use disorder.
D - Hydroxyzine is sedating and not considered first-line due to anticholinergic effects.
Reference: APA Practice Guideline for GAD (2023); Bandelow, B., et al. (2023). World J Biol Psychiatry.
Page 3
, Q5. A patient with bipolar I disorder is maintained on lithium 900 mg daily (serum level 0.8
mEq/L). They develop coarse tremor, nausea, and slurred speech after starting lisinopril for
hypertension. What is the most likely cause?
A. Lithium toxicity due to reduced renal clearance
B. Serotonin syndrome from drug interaction
C. Neuroleptic malignant syndrome
D. Extrapyramidal symptoms from lithium
Correct Answer: A. Lithium toxicity due to reduced renal clearance
Rationale: ACE inhibitors like lisinopril reduce glomerular filtration rate, decreasing lithium clearance
and increasing serum levels, leading to toxicity. Symptoms of lithium toxicity include coarse tremor,
nausea, slurred speech, and ataxia. Serotonin syndrome (B) involves autonomic instability and
hyperthermia. NMS (C) is associated with antipsychotics. EPS (D) is not typical for lithium.
Why Wrong:
B - Serotonin syndrome requires serotonergic agents and presents with hyperthermia, rigidity, and
autonomic instability.
C - NMS is associated with antipsychotics, not lithium.
D - Extrapyramidal symptoms are not a classic effect of lithium.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 17; Finley, P.R. (2016).
Clin Pharmacokinet.
Q6. A patient with ADHD is being treated with methylphenidate extended-release 36 mg daily. They
report significant appetite suppression and insomnia. Which management strategy is most
appropriate?
A. Switch to immediate-release methylphenidate given three times daily
B. Add guanfacine 1 mg at bedtime
C. Decrease dose to 18 mg and add bupropion 150 mg daily
D. Administer methylphenidate with a high-protein breakfast
Correct Answer: B. Add guanfacine 1 mg at bedtime
Rationale: Adding an alpha-2 agonist like guanfacine can offset stimulant side effects (appetite
suppression, insomnia) and improve ADHD symptom control. Switching to immediate-release (A) may
worsen rebound effects. Decreasing dose and adding bupropion (C) is not standard. High-protein
breakfast (D) does not significantly mitigate appetite suppression.
Why Wrong:
A - Immediate-release methylphenidate may cause more frequent rebound and does not improve
sleep.
C - Bupropion is not FDA-approved for ADHD and has its own side effects.
D - Protein intake does not meaningfully reduce appetite suppression or insomnia.
Reference: Pliszka, S.R. (2022). AACAP Practice Parameter for ADHD; Childress, A.C. (2020). J Child
Adolesc Psychopharmacol.
Page 4
Exam Prep Document | 2026/2027 Edition | 250 Verified
Questions
NRNP 6665 PMHNP Care Across the Lifespan I Midterm Exam 2026-2027 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive midterm exam preparation resource for NRNP 6665 PMHNP Care Across the
Lifespan I contains 250 verified questions with detailed rationales. Designed for the 2026/2027
academic year, it covers all major content areas including psychiatric assessment, therapeutic
interventions, and lifespan considerations. Each question includes evidence-based explanations to
reinforce learning and ensure exam readiness. This document is pass guaranteed and A+ graded.
Abstract:
This document provides a rigorous preparation tool for the NRNP 6665 PMHNP Care Across the Lifespan I
midterm examination, featuring 250 verified questions with detailed rationales. The content is meticulously aligned
with the 2026/2027 academic year curriculum and the latest psychiatric-mental health nursing standards. Each
question is designed to test critical thinking and clinical application across diverse patient populations, from
children to older adults. The rationales include evidence-based explanations, distractor analyses, and references to
key sources such as the DSM-5-TR and APA guidelines. This resource emphasizes safe, effective, and culturally
competent care, ensuring students are well-prepared for both the exam and future clinical practice. The pass
guarantee and A+ grading reflect the high quality and accuracy of the material.
Content Area Overview:
Content Area Questions Key Topics Weight
Foundations of 1-50 Therapeutic communication, ethical 20%
Psychiatric-Mental Health principles, legal issues, cultural competence,
Nursing patient advocacy
Psychiatric Assessment and 51-100 Mental status exam, diagnostic criteria 20%
Diagnosis (DSM-5-TR), risk assessment, differential
diagnosis, biopsychosocial formulation
Psychopharmacology 101-150 Antidepressants, antipsychotics, mood 20%
stabilizers, anxiolytics, stimulants, side
effect management
Therapeutic Interventions 151-200 Cognitive-behavioral therapy, motivational 20%
interviewing, crisis intervention,
psychoeducation, family therapy
Lifespan Considerations 201-250 Child and adolescent psychiatry, geriatric 20%
psychiatry, perinatal mental health,
developmental transitions, special
populations
Page 1
,Q1. A patient with treatment-resistant depression has failed adequate trials of three SSRIs and one
SNRI. They also have a history of hypomania when previously treated with venlafaxine. Which
augmentation strategy is most appropriate while minimizing mood destabilization risk?
A. Add aripiprazole 2 mg daily
B. Add lithium 300 mg twice daily
C. Switch to phenelzine 45 mg daily
D. Add bupropion 150 mg extended-release daily
Correct Answer: A. Add aripiprazole 2 mg daily
Rationale: Aripiprazole is FDA-approved for adjunctive treatment of major depressive disorder and has
a low risk of inducing mania compared to other agents. Lithium is effective but requires monitoring and
may not be first-line augmentation for unipolar depression. Phenelzine is a potent MAOI with dietary
restrictions and higher risk. Bupropion can lower seizure threshold and is not recommended in patients
with bipolar diathesis.
Why Wrong:
B - Lithium requires serum monitoring and is not first-line augmentation for unipolar depression; it
also carries risk of toxicity.
C - Phenelzine has significant dietary restrictions and MAOI interactions; not first-line for
augmentation.
D - Bupropion can lower seizure threshold and may destabilize mood in patients with bipolar
diathesis.
Reference: Stahl, S.M. (2021). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 6; APA Practice
Guideline for MDD (2010, updated 2023).
Q2. Which neurobiological finding best explains the therapeutic lag of SSRIs in major depressive
disorder despite immediate increases in synaptic serotonin?
A. Downregulation of presynaptic 5-HT1A autoreceptors
B. Upregulation of postsynaptic 5-HT2A receptors
C. Inhibition of serotonin transporter (SERT) within hours
D. Desensitization of somatodendritic 5-HT1A autoreceptors
Correct Answer: D. Desensitization of somatodendritic 5-HT1A autoreceptors
Rationale: SSRIs rapidly block SERT, increasing extracellular serotonin, but clinical response requires
weeks because somatodendritic 5-HT1A autoreceptors in the raphe nuclei must desensitize to allow
sustained serotonin release. Downregulation of presynaptic 5-HT1A autoreceptors (A) is less relevant;
upregulation of 5-HT2A (B) is associated with side effects; SERT inhibition (C) occurs immediately but
does not explain the lag.
Why Wrong:
A - Presynaptic 5-HT1A autoreceptors are on terminals, but their downregulation is not the primary
mechanism for the lag.
B - Upregulation of 5-HT2A receptors is linked to anxiety and insomnia, not therapeutic lag.
C - SERT inhibition occurs within hours, but does not account for the delayed clinical effect.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 15; Stahl, S.M. (2021).
Stahl's Essential Psychopharmacology, Ch. 6.
Page 2
,Q3. A patient with schizophrenia is stabilized on haloperidol decanoate 100 mg IM every 4 weeks.
They present with acute dystonia after a missed dose. Which intervention is most appropriate for
immediate management?
A. Administer benztropine 2 mg IM
B. Increase haloperidol dose to 150 mg
C. Start olanzapine 10 mg orally
D. Give diphenhydramine 50 mg IV
Correct Answer: A. Administer benztropine 2 mg IM
Rationale: Acute dystonia is an extrapyramidal symptom (EPS) caused by dopamine blockade.
Anticholinergic agents like benztropine IM provide rapid symptom relief. Diphenhydramine IV (D) is also
effective but more sedating; benztropine is preferred for dystonia. Increasing haloperidol (B) would
worsen EPS. Starting olanzapine (C) does not address the acute dystonia.
Why Wrong:
B - Increasing the dose of a high-potency antipsychotic would exacerbate EPS.
C - Olanzapine has lower EPS risk but does not treat acute dystonia.
D - Diphenhydramine IV is effective but more sedating; benztropine IM is more specific.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 16; APA Practice
Guideline for Schizophrenia (2021).
Q4. A patient with generalized anxiety disorder (GAD) has a history of substance use disorder
(alcohol in remission). Which first-line pharmacotherapy is safest given this history?
A. Buspirone 10 mg three times daily
B. Lorazepam 0.5 mg three times daily as needed
C. Sertraline 50 mg daily
D. Hydroxyzine 25 mg four times daily
Correct Answer: C. Sertraline 50 mg daily
Rationale: SSRIs (sertraline) are first-line for GAD and have no abuse potential, making them safest in
patients with substance use history. Buspirone (A) is non-addictive but less effective for GAD.
Benzodiazepines (B) carry high abuse risk. Hydroxyzine (D) is sedating and not first-line.
Why Wrong:
A - Buspirone is non-addictive but less effective than SSRIs for GAD.
B - Benzodiazepines have high abuse potential in patients with substance use disorder.
D - Hydroxyzine is sedating and not considered first-line due to anticholinergic effects.
Reference: APA Practice Guideline for GAD (2023); Bandelow, B., et al. (2023). World J Biol Psychiatry.
Page 3
, Q5. A patient with bipolar I disorder is maintained on lithium 900 mg daily (serum level 0.8
mEq/L). They develop coarse tremor, nausea, and slurred speech after starting lisinopril for
hypertension. What is the most likely cause?
A. Lithium toxicity due to reduced renal clearance
B. Serotonin syndrome from drug interaction
C. Neuroleptic malignant syndrome
D. Extrapyramidal symptoms from lithium
Correct Answer: A. Lithium toxicity due to reduced renal clearance
Rationale: ACE inhibitors like lisinopril reduce glomerular filtration rate, decreasing lithium clearance
and increasing serum levels, leading to toxicity. Symptoms of lithium toxicity include coarse tremor,
nausea, slurred speech, and ataxia. Serotonin syndrome (B) involves autonomic instability and
hyperthermia. NMS (C) is associated with antipsychotics. EPS (D) is not typical for lithium.
Why Wrong:
B - Serotonin syndrome requires serotonergic agents and presents with hyperthermia, rigidity, and
autonomic instability.
C - NMS is associated with antipsychotics, not lithium.
D - Extrapyramidal symptoms are not a classic effect of lithium.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 17; Finley, P.R. (2016).
Clin Pharmacokinet.
Q6. A patient with ADHD is being treated with methylphenidate extended-release 36 mg daily. They
report significant appetite suppression and insomnia. Which management strategy is most
appropriate?
A. Switch to immediate-release methylphenidate given three times daily
B. Add guanfacine 1 mg at bedtime
C. Decrease dose to 18 mg and add bupropion 150 mg daily
D. Administer methylphenidate with a high-protein breakfast
Correct Answer: B. Add guanfacine 1 mg at bedtime
Rationale: Adding an alpha-2 agonist like guanfacine can offset stimulant side effects (appetite
suppression, insomnia) and improve ADHD symptom control. Switching to immediate-release (A) may
worsen rebound effects. Decreasing dose and adding bupropion (C) is not standard. High-protein
breakfast (D) does not significantly mitigate appetite suppression.
Why Wrong:
A - Immediate-release methylphenidate may cause more frequent rebound and does not improve
sleep.
C - Bupropion is not FDA-approved for ADHD and has its own side effects.
D - Protein intake does not meaningfully reduce appetite suppression or insomnia.
Reference: Pliszka, S.R. (2022). AACAP Practice Parameter for ADHD; Childress, A.C. (2020). J Child
Adolesc Psychopharmacol.
Page 4
